Radiopharm Theranostics Ltd (ASX:RAD) will present its interim data from Imperial College London’s F-18 Pivalate Phase 2a imaging trial in brain metastases, funded by the Medical Research Council, at the 34th EORTC/AACR/NCI symposium in Barcelona from October 26-28.
The data will also be published in a peer-reviewed journal.
Presentation of the data in both formats gives strong validation to the work the company is doing in the field of cancer diagnostics and therapeutics.
Promising theranostic approach
“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented,” Radiopharm’s CEO and managing director Riccardo Canevari said.
“The team at Imperial College London, led by Professor Aboagye, did a tremendous job. F18-Pivalate and its potential therapeutic variations, currently under development, represent a promising theranostic approach to target brain metastases and potentially other brain tumours.”
Professor Aboagye added: “We’re very excited to present our interim data soon. A potentially innovative and effective new imaging approach will be more than welcomed in this field.”
Hitting its milestones
RAD, developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, has also acquired an exclusive worldwide licence for the Pivalate platform technology from Cancer Research Technology Limited and Imperial College London, and has a Sponsored Research Agreement on new analogues with its inventor Professor Eric Aboagye.
And just yesterday, the company announced it entered into a clinical supply agreement with SHINE Technologies, a next-generation fusion technology company, which will see SHINE supply isotope non-carrier-added lutetium-177 (Lu-177) to help RAD develop its clinical pipeline of diagnostic and therapeutic radiopharmaceutical products.
Read more: Radiopharm Theranostics enters supply agreement to strengthen clinical pipeline of radiopharmaceutical products